Cowen analyst Ken Cacciatore is the latest to defend Coherus Biosciences (NASDAQ: CHRS), reiterating an Outperform rating and price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE